Xtant Medical Q3 2022 revenue $14.5M (+5% YoY); net loss widens to $2.4M

Xtant Medical Holdings, Inc.

2022-Q3 EPS reported -$0.07 revenue$42,699,000

Revenue of $14.5M, up 5% from $13.8M in Q3 2021, driven by 12% biologics growth from OsteoFactor and OsteoVive Plus launches.
Gross margin improved to 54.6% from 52.2% on better capacity utilization.
Net loss of $2.4M ($0.03 loss per share) vs. $1.8M ($0.02) in prior-year period.
Non-GAAP adjusted EBITDA loss of $0.9M, compared to $0.6M loss a year ago.
CEO cited recent $9.75M private placement to support growth and expects full operating capacity by Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xtant Medical Holdings, Inc. reported third quarter ended September 30, 2022 results: revenue $14.5 million, net income $2.4 million, EPS $0.03 per share.

Period: third quarter ended September 30, 2022
Revenue: $14.5 million
Net income: $2.4 million
EPS: $0.03 per share
Result: reported results

Exact text from the filing

by the first quarter of 2023 enabling our team to take advantage of the robust demand environment.” Third Quarter 2022 Financial Results Third quarter 2022 revenue was $14.5 million, compared to $13.8 million for the same quarter in 2021. The increase in revenue was largely attributable to introductions of new products. Gross margin for the third quarter of

View on SEC.gov

Browse all earnings releases →

Xtant Medical Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-030277

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.